Neuromuskulaarisen sähköstimulaation arviointi fyysisen aktiivisuusohjelman lisäksi (HORMES)

Inclusion Criteria:

• Patient treated with pharmacological androgen deprivation therapy for prostate cancer for more than 26 weeks;
• Performance index (WHO): 0 or 1;
• Patient able to understand the information related to the study, to read the information leaflet and having consented to participate in the study;
• Patient benefiting from a social security scheme;

Exclusion Criteria:

• Weight ≥ 130 kg;
• Vegetarian food;
• Other associated neoplasia;
• Patient having undergone a bilateral orchiectomy;
• Painful bone metastases, or at risk of fracture;
• Anemia (hemoglobin < 10 g/dL);
• Thrombocytopenia (platelets < 50 G/L);
• Renal impairment (creatinine clearance < 60 mL/min, or albuminuria > 30);
• Patient planning to travel more than 4 weeks continuously in the next 52 weeks;
• Absolute contraindication to physical training (e.g. musculoskeletal, cardiovascular or neurological disorders), according to the doctor specializing in the associated medical condition;
• Contraindication to the use of the neuromuscular electrostimulation device or the impedance meter, in particular infectious disease in the acute phase, fungal infection, dermatitis, unbalanced arrhythmia, epilepsy, wearing an active implantable device (pacemaker, heart artificial, prosthesis incorporating an electromagnetic system), open wound;
• Sports activity already supervised by a third party or at an equal or higher level than the bodybuilding/muscle strengthening work recommended in the study;
• Protected adult patient (under guardianship or curatorship, or under a regime of deprivation of liberty);
• Patient participating in another research, or in a period of exclusion from another research.